Graphite Bio has agreed to merge into LENZ Therapeutics, creating a combined company focused on advancing LENZ’s lead pipeline candidates, designed to address presbyopia—nearly a year after Graphite ...
The first patient treated with Graphite Bio's gene-editing program suffered a serious side effect. The biotech halted the trial while it investigates the case, which may impact other CRISPR companies.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to ...
One dose, one cure. Countless researchers with this dream have worked for decades toward developing life-saving medicines for genetic diseases. That’s gene therapy’s goal: to fix DNA errors and see a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results